Maret Pharmaceuticals Presents Promising Phase I Clinical MARstem™ Results at International Symposium on New Drugs in Cancer Therapy

Newport Beach, CA, November 10, 2000 — Maret Pharmaceuticals, Inc. today reported positive Phase I clinical results that demonstrate the potential of MARstem™ as a multilineage hematopoietic therapy (multiple blood cell stimulant) to treat or prevent pancytopenia (a reduction in different types of blood cells) following chemotherapy in breast cancer patients. The study was selected as a late breaking abstract at the 11th National Cancer Institute – European Organization for Research and Treatment of Cancer – American Association for Cancer Research (NCI-EORTC-AACR) Symposium on New Drugs in Cancer Therapy.
Continue reading “Maret Pharmaceuticals Presents Promising Phase I Clinical MARstem™ Results at International Symposium on New Drugs in Cancer Therapy”

Maret Pharmaceuticals Demonstrates Angiotensin’s Activity on Early and Late Stage Progenitors

Newport Beach, CA, August 23, 2000 — Maret Pharmaceuticals, Inc. announced today that University of Southern California researchers published the first direct evidence that Angiotensin II (AII), a natural peptide hormone, acts upon early progenitor cells to stimulate blood cell growth, or hematopoiesis. Research published in the August 2000 issue of Stem Cells supports Maret’s lead drug candidate program for MARstem, which is an analog of AII without its effects on blood pressure. MARstem is currently undergoing Phase I/II clinical trials to evaluate effects in correcting anemia (a lack of red blood cells) in chronic renal failure patients and in deficiencies of white cells, red cells, and platelets following chemotherapy in cancer patients.
Continue reading “Maret Pharmaceuticals Demonstrates Angiotensin’s Activity on Early and Late Stage Progenitors”

Maret Initiates Second Clinical Trial With MARstem™. Company cleared for study to correct anemia in chronic renal failure patients

Newport Beach, CA, June 7, 2000 — Maret Pharmaceuticals, Inc. announced today that it has commenced its second human clinical trial for MARstem™, the Company’s lead drug candidate. MARstem, a peptide analog of the human hormone angiotensin, will be studied in a Phase I/II trial to evaluate the drug’s safety and its ability to restore red blood cells to minimize anemia in end stage renal disease (ESRD) patients. The study is part of Maret’s clinical program to assess the broad hematopoietic (blood cell growth) effects of MARstem.
Continue reading “Maret Initiates Second Clinical Trial With MARstem™. Company cleared for study to correct anemia in chronic renal failure patients”

Maret Initiates Clinical Development Program With Lead Peptide For Chemotherapy Induced Neutropenia

Newport Beach, CA, December 2, 1999 — Maret Pharmaceuticals, Inc. announced today that it has commenced human clinical trials of its lead drug candidate, a peptide analog of the human hormone angiotensin, known as MARstem™. The initial Phase I/II study will evaluate the safety and potential therapeutic activity of MARstem in limiting neutropenia (a decrease in white blood cells) following chemotherapy.
Continue reading “Maret Initiates Clinical Development Program With Lead Peptide For Chemotherapy Induced Neutropenia”